Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company offers non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS), including Navigated Brain Stimulation (NBS) system 6 for presurgical mapping of the speech and motor cortices of the brain, for the treatment of major depression and chronic unilateral neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb. The company markets and sells its diagnostics systems to universities and teaching hospitals. It has an exclusive collaboration with Sinaptica Therapeutics, Inc. for the development, manufacture, and delivery of precision neuromodulation system for the treatment of Alzheimer's disease and mild cognitive impairment; and a development and distribution collaboration with Brainlab AG for motor and speech mapping systems. The company was incorporated in 2000 and is headquartered in Helsinki, Finland.
Frequently asked questions
What sector does Nexstim Oyj (NXTMH) operate in?
Nexstim Oyj belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Nexstim Oyj (NXTMH) current stock price?
As of the latest data, Nexstim Oyj stock price is €9.63, with a previous close of €9.64. Nexstim Oyj lost -€0.01 in the last trading session, representing a -0.1% loss.
What is Nexstim Oyj (NXTMH) current market capitalization?
Nexstim Oyj market cap is approximately 69.67 million.
What is Nexstim Oyj (NXTMH) Earnings Per Share (EPS)?
The trailing EPS is €0.08, and the forward EPS is €0.27.
What is Nexstim Oyj (NXTMH) Price-to-Earnings (P/E) ratio?
Nexstim Oyj current P/E ratio is 120.38, with a forward P/E of 35.67.
Does Nexstim Oyj (NXTMH) pay dividends?
No. Nexstim Oyj does not pay a dividend.
What is Nexstim Oyj (NXTMH) beta (volatility) score?
Nexstim Oyj has a beta of 0.442, indicating lower volatility than the overall market.
